Results11 Jun 2018 11:14
SFX-01 is proving to be well tolerated with no safety concerns arising and shows encouraging early signs of anti-tumour activity: ( lets see what the experts make out of it)
- Four patients had their disease stabilised (that is, having joined the trial with progressive disease their tumours stopped progressing) for the full duration of the study through to, and including, a favourable final scan result at week 24. Of these four patients, one also had a partial response which is a reduction in tumour size of at least 30% on one scan.